OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - ASTRAZENECA | Market Closed - Börse Stuttgart 12:08:37 21/06/2024 pm IST | ||
| 8.18 EUR | +0.12% |
|
| Current month | +4.61% | ||
| 1 month | +5.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 21/24/21 | 8.18 | +0.12% |
| 20/24/20 | 8.17 | +0.37% |
| 19/24/19 | 8.14 | -1.93% |
| 18/24/18 | 8.3 | -1.07% |
| 17/24/17 | 8.39 | +1.45% |
Delayed Quote Börse Stuttgart
Last update June 21, 2024 at 12:08 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | CU2ATY |
| ISIN | DE000CU2ATY7 |
| Date issued | 17/04/2019 |
| Strike | 5,473 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.41 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.5 € |
|---|---|
| Lowest since issue | 1.01 € |
| Spread | 0.13 € |
| Spread % | 1.54% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.2
USD
Average target price
174.4
USD
Spread / Average Target
+11.00%
- Stock Market
- Certificates
- Certificat
